No association between recurrent implantation failure (RIF) following in vitro Fertilization (IVF) with gene Polymorphism (P53 Arg72Pro)

Document Type : Original Article

Authors

1 Msc student, Department of Biology, School of Basic Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

2 Professor, Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Assistant professor, Department of Biology, School of Basic Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

4 Physician, Montaserieh Infertility Treatment Center, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Msc student, Department of Human Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Assistant professor, Department of Obstetrics and Gynecology, Women's Health Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

7 Assistant professor, Department of Biochemistry, School of Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

8 Assistant professor, Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: recurrent implantation failure (RIF) is the most common cause of pregnancy failure after in vitro fertilization (IVF). Among the different causes of RIF, the role of maternal genetics factors is as one of most important factors. P53 codon 72 polymorphism is one of the notable polymorphisms in this field. According to evidences about the association between P53 polymorphism and increased risk of RIF in different population, if this relationship be justified in Iranian population, this polymorphism can be used to predict IVF success rate.  This study was performed with aim to evaluate the association between this polymorphism and incidence of RIF.
Methods: This case-control study was performed on 80 infertile couples in Mashhad Montaserieh Infertility Treatment Center in 2010. The infertile couples were divided into three groups of control, RIF-1, and RIF-2. The control group included 40 women who were successfully pregnant after IVF. The patient group 1 were 20 women who no type of pregnancy was observed after two IVF, and patient group 2 were 20 women who failed to be pregnant after at least three IVF. P53 gene polymorphism genotype (Arg72pro allele) was determined using PCR- ARMS technique. Statistical analysis was performed by SPSS software (version 16) and Pearson Chi-Square test. PResults: The frequency of Arg/Pro genotype in control group, patient group 1, patient group 2 and total patients was 92.5%, 75%, 80% and 77.5%. The frequency of Arg/Arg genotype in these groups was 7.5%, 25%, 20% and 22.5%, respectively. Pro/Pro genotype was observed in none of the groups. According to Pearson Chi-square test results, distribution of genotypes was not significantly different between patient group 1 and patient group 2 and also total patients in comparison with control group.
Conclusion: According to the results of present study in the studied population, there is no association between P53 codon 72 polymorphism and occurrence of RIF. So this polymorphism cannot be used to predict the risk of RIF.

Keywords

References

  1. Edwards RG. IVF, IVM, natural cycle IVF, minimal stimulation IVF–time for a rethink. Reprod Biomed Online 2007; 15(1):106-19.
  2. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. Philadelphia: Lippincott Williams & Wilkins; 2005.
  3. Fiedler K, Wurfel W. Effectively of heparin in assisted reproduction. Eur J Med Res 2004; 9(4):207-14.
  4. Raziel A, Friedler S, Schachter M, Kasterstein E, Strassburger D, Ron-El R. Increased frequency of female partner chromosomal abnormalities in patients with high-order implantation failure after in vitro fertilization. Fertil steril 2002; 78(3):515-9.
  5. Oliveira FG, Abdelmassih VG, Diamond MP, Dozortsev D, Nagy ZP, Abdelmassih R. Uterine cavity findings and hysteroscopic interventions in patients undergoing in vitro fertilization–embryo transfer who repeatedly cannot conceive. Fertil steril 2003; 80(6):1371-5.
  6. De Klerk C, Macklon NS, Heijnen EM, Eijkemans MJ, Fauser BC, Passchier J, et al. The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy. Hum Reprod 2007; 22(9):2554-8.
  7. Bagchi IC, Kumar S. Steroid-regulated molecular markers of implantation. Semin Reprod Endocrinol 1999; 17(3):235-40.
  8. Hines RS. Molecular analysis of implantation. Semin Reprod Med 2000; 18(1):91-6.
  9. Paria BC, Lim H, Das SK, Reese J, Dey SK. Molecular signaling in uterine receptivity for implantation. Semin Cell Dev Biol 2000; 11(2):67-76.
  10. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005; 222(1):57-65.
  11. Haggarty P, McCallum H, McBain H, Andrews K, Duthie S, McNeill G, et al. Effect of B vitamins and genetics on success of in-vitro fertilisation: prospective cohort study. Lancet 2006; 367(9521):1513-9.
  12. Dobson A, Davis RM, Rosen MP, Shen S, Rinaudo P, Chan J, et al. Methylenetetrahydrofolate reductase C677T and A1298C variants do not affect ongoing pregnancy rates following IVF. Hum Reprod 2007; 22(2):450-6.
  13. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 2006; 12(3):322-7.
  14. Wunsch A, Ahda Y, Banaz-Yaşar F, Sonntag B, Nieschlag E, Simoni M, et al. Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor. Fertil Steril 2005; 84(2):446-53.
  15. Cramer DW, Hornstein MD, McShane P, Powers RD, Lescault PJ, Vitonis AF, et al. Human progesterone receptor polymorphisms and implantation failure during in vitro fertilization. Am J Obstet Gynecol 2003; 189(4):1085-92.
  16. Georgiou I, Konstantelli M, Syrrou M, Messinis IE, Lolis DE. Oestrogen receptor gene polymorphisms and ovarian stimulation for in-vitro fertilization. Hum Reprod 1997; 12(7):1430-3.
  17. Klinkert ER, te Velde ER, Weima S, van Zandvoort PM, Hanssen RG, Nilsson PR, et al. FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod Biomed Online 2006; 13(5):687-95.
  18. Liu H, Li B. P53 control of bone remodeling. J Cell Biochem 2010; 111(3):529-34.
  19. Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q, et al. P53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 2006; 172(1):115-25.
  20. Sakai A, Sakata T, Tanaka S, Okazaki R, Kunugita N, Norimura T, et al. Disruption of the p53 gene results in preserved trabecular bone mass and bone formation after mechanical unloading. J Bone Miner Res 2002; 17(1):119-27.
  21. Darzynkiewicz Z. Another "Janus paradox" of p53: induction of cell senescence versus quiescence. Aging (Albany NY) 2010; 2(6):329-30.
  22. Kailong L, Du X, Yani H, Lin Z, Jvrong Y, Ruihua S, et al. P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury. Biocell 2007; 31(2):213-23.
  23. Hu W, Feng Z, Teresky AK, Levine AJ. P53 regulates maternal reproduction through LIF. Nature 2007; 450(7170):721-4.
  24. Varley J. Germline TP53 mutations and Li‐Fraumeni syndrome. Hum Mutat 2003; 21(3):313-20.
  25. Brenna S, Silva ID, Zeferino LC, Pereira JS, Martinez EZ, Syrjänen KJ. Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol Oncol 2004; 93(2):374-80.
  26. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001; 114(Pt 23):4139-40.
  27. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408(6810):307-10.
  28. Riley KJ, Maher LJ 3rd. P53–RNA interactions: new clues in an old mystery. RNA 2007; 13(11):1825-33.
  29. Singh V, Rastogi N, Mathur N, Singh K, Singh MP. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 2008; 18(1):48-57.
  30. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer cell 2007; 12(4):303-12.
  31. Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J urol 1999; 162(4):1496-501.
  32. Rosai J. Female reproductive system. Rosai and Ackermans. Surgical pathology. 2th ed. St Louis: Editorial Mosby; 1996.
  33. Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol 2007; 8(4):275-83.
  34. Strandell A, Lindhard A, Waldenström U, Thorburn J, Janson PO, Hamberger L. Hydrosalpinx and IVF outcome: a prospective, randomized multicentre trial in Scandinavia on salpingectomy prior to IVF. Hum Reprod 1999; 14(11):2762-9.
  35. Kang HJ, Feng Z, Sun Y, Atwal G, Murphy ME, Rebbeck TR, et al. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A 2009; 106(24):9761-6.
  36. Kay C, Jeyendran RC, Coulam CB. P53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. Reprod Biomed Online 2006; 13(4):492-6.
  37. Goodman C, Jeyendran RS, Coulam C. P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure. Fertil Steril 2009; 92(2):494-8.
  38. Patounakis G, Treff N, Tao X, Lonczak A, Scott RT Jr, Frattarelli JL. The p53 codon 72 single nucleotide polymorphism lacks a significant effect on implantation rate in fresh in vitro fertilization cycles: an analysis of 1,056 patients. Fertil Steril 2009; 92(4):1290-6.
  39. Aryanpur M, Heydari G, Tarahomi M, Akhondi MM, Zeraati H, Masjedi MR. Prevalence of tobacco smoking among infertile couples in Tehran. J Reprod Infertil 2009; 9(4):342-9. (Persian).

Files

Share

How to cite

Statistics